

Francisco M Vega

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6709790/publications.pdf>

Version: 2024-02-01

36
papers

2,393
citations

304743

22
h-index

454955

30
g-index

38
all docs

38
docs citations

38
times ranked

3553
citing authors

#	ARTICLE	IF	CITATIONS
1	Rho GTPases in cancer cell biology. FEBS Letters, 2008, 582, 2093-2101.	2.8	652
2	RhoA and RhoC have distinct roles in migration and invasion by acting through different targets. Journal of Cell Biology, 2011, 193, 655-665.	5.2	227
3	Rac1 and Rac2 regulate macrophage morphology but are not essential for migration. Journal of Cell Science, 2006, 119, 2749-2757.	2.0	168
4	Cdc42 promotes transendothelial migration of cancer cells through β 1 integrin. Journal of Cell Biology, 2012, 199, 653-668.	5.2	160
5	p53 Stabilization and Accumulation Induced by Human Vaccinia-Related Kinase 1. Molecular and Cellular Biology, 2004, 24, 10366-10380.	2.3	125
6	Human Vaccinia-related Kinase 1 (VRK1) Activates the ATF2 Transcriptional Activity by Novel Phosphorylation on Thr-73 and Ser-62 and Cooperates with JNK. Journal of Biological Chemistry, 2004, 279, 27458-27465.	3.4	110
7	c-Jun phosphorylation by the human vaccinia-related kinase 1 (VRK1) and its cooperation with the N-terminal kinase of c-Jun (JNK). Oncogene, 2004, 23, 8950-8958.	5.9	100
8	VRK1 Signaling Pathway in the Context of the Proliferation Phenotype in Head and Neck Squamous Cell Carcinoma. Molecular Cancer Research, 2006, 4, 177-185.	3.4	78
9	Roles of VRK1 as a new player in the control of biological processes required for cell division. Cellular Signalling, 2011, 23, 1267-1272.	3.6	78
10	The subcellular localization of vaccinia-related kinase-2 (VRK2) isoforms determines their different effect on p53 stability in tumour cell lines. FEBS Journal, 2006, 273, 2487-2504.	4.7	72
11	The RhoB small GTPase in physiology and disease. Small GTPases, 2018, 9, 384-393.	1.6	62
12	Expression of the VRK (vaccinia-related kinase) gene family of p53 regulators in murine hematopoietic development. FEBS Letters, 2003, 544, 176-180.	2.8	60
13	SnapShot: Rho Family GTPases. Cell, 2007, 129, 1430.e1-1430.e2.	28.9	55
14	p53 Downregulates Its Activating Vaccinia-Related Kinase 1, Forming a New Autoregulatory Loop. Molecular and Cellular Biology, 2006, 26, 4782-4793.	2.3	54
15	RhoB regulates cell migration through altered focal adhesion dynamics. Open Biology, 2012, 2, 120076.	3.6	52
16	Kinetic Properties of p53 Phosphorylation by the Human Vaccinia-Related Kinase 1. Archives of Biochemistry and Biophysics, 2002, 399, 1-5.	3.0	51
17	Identification of a dominant epitope in human vaccinia-related kinase 1 (VRK1) and detection of different intracellular subpopulations. Archives of Biochemistry and Biophysics, 2007, 465, 219-226.	3.0	49
18	The vaccinia virus B1R kinase induces p53 downregulation by an Mdm2-dependent mechanism. Virology, 2004, 328, 254-265.	2.4	40

#	ARTICLE	IF	CITATIONS
19	CD44-high neural crest stem-like cells are associated with tumour aggressiveness and poor survival in neuroblastoma tumours. <i>EBioMedicine</i> , 2019, 49, 82-95.	6.1	32
20	The C/H3 Domain of p300 Is Required to Protect VRK1 and VRK2 from their Downregulation Induced by p53. <i>PLoS ONE</i> , 2008, 3, e2649.	2.5	28
21	The Rho GTPase RhoB regulates cadherin expression and epithelial cell-cell interaction. <i>Cell Communication and Signaling</i> , 2015, 13, 6.	6.5	26
22	Association of high microvessel density and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126. <i>Oncotarget</i> , 2017, 8, 52193-52210.	1.8	24
23	Hypoxia in the Initiation and Progression of Neuroblastoma Tumours. <i>International Journal of Molecular Sciences</i> , 2020, 21, 39.	4.1	21
24	Identification of VRK1 as a New Neuroblastoma Tumor Progression Marker Regulating Cell Proliferation. <i>Cancers</i> , 2020, 12, 3465.	3.7	15
25	Oncogenic Sox2 regulates and cooperates with VRK1 in cell cycle progression and differentiation. <i>Scientific Reports</i> , 2016, 6, 28532.	3.3	14
26	The atheroma plaque secretome stimulates the mobilization of endothelial progenitor cells ex vivo. <i>Journal of Molecular and Cellular Cardiology</i> , 2017, 105, 12-23.	1.9	14
27	Characterisation of tumoral markers correlated with ErbB2 (HER2/Neu) overexpression and metastasis in breast cancer. <i>Proteomics - Clinical Applications</i> , 2008, 2, 1313-1326.	1.6	11
28	A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity. <i>Cell Discovery</i> , 2020, 6, 49.	6.7	10
29	Neural crest derived progenitor cells contribute to tumor stroma and aggressiveness in stage 4/M neuroblastoma. <i>Oncotarget</i> , 2017, 8, 89775-89792.	1.8	4
30	Response to High CD44 expression is not a prognosis marker in patients with high-risk neuroblastoma. <i>EBioMedicine</i> , 2020, 53, 102703.	6.1	0
31	Non-Canonical Kinases and Substrates in Cancer Progression. <i>Cancers</i> , 2021, 13, 1628.	3.7	0
32	VRK1 (Vaccinia-related kinase 1). <i>Atlas of Genetics and Cytogenetics in Oncology and Haematology</i> , 2008, , .	0.1	0
33	RhoC (RHOC)., 2016, , 1-9.		0
34	Abstract LB-298: The novel triple PI3K-CDK4/6-BRD4 inhibitor SRX3177 harnesses synthetic lethality relationships to orthogonally disrupt cancer cell signaling. , 2017, , .		0
35	RhoC (RHOC)., 2018, , 4691-4699.		0
36	A protocol to enrich in undifferentiated cells from neuroblastoma tumor tissue samples and cell lines. <i>STAR Protocols</i> , 2022, 3, 101260.	1.2	0